ClinicalTrials.gg
RecruitingNCT04544774Updated May 1, 2026

The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy

An observational study in Perennial Allergic Rhinitis, Seasonal Allergic Rhinitis and Local Allergic Rhinitis, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 2 sites in Belgium. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This prospective multicentric academic NAPT study aims to compile a database of all patients who initiate immunotherapy.

The NAPT will take place before, during and after AIT to evaluate the cost and effectiveness of the treatment. The study consists of 4 visits and 2 telephone contacts that are repeated annually for 3 years.

This study will be conducted in 2 hospitals: UZ Leuven and AZ ST. Jan Brugge on the consultation Ear, Nose and Throat Diseases (ENT) and the department of Internal Medicine / Allergology

02

Conditions studied

  • Perennial Allergic Rhinitis
  • Seasonal Allergic Rhinitis
  • Local Allergic Rhinitis
03

In context

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

This study's planned enrollment of 200 is below the median of 682 across 18 observational studies indexed under Rhinitis, Allergic, Perennial.

Browse Rhinitis, Allergic, Perennial studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with persistent and intermittent allergic rhinitis who start with AIT treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 and ≤60 years
  • Persistent or intermittent allergic rhinitis complaints, confirmed by SPT and/of immunocap for the specific IgEs.

OR suspected local allergic rhinitis

  • Patients who start with AIT treatment
  • The patient must be motivated and willing to come to all visits
  • The patient must be able to understand and sign the

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled asthma
  • Conditions affecting the functioning of the immune system (eg: immune deficiencies, , diseases)
  • Use of β-blockers, or ACE inhibitors
  • to aluminum hydroxide and/or hypersensitivity to any of the in AIT
  • Anaphylaxis after allergen challenge in the past
  • Acute rhinosinusitis in the last 12 weeks
  • Recent surgery on the nose and/or paranasal sinuses in the last 12 weeks
  • Pregnancy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Allergic rhinitis patients

    Patients with persistent or intermittent allergic rhinitis complaints, confirmed by skin prick tests and/or immunocap for specific IgEs, that start with AIT treatment.

    Drug: AIT · Diagnostic Test: NAPT

Interventions

  • DrugAIT

    AIT for airborn allergens (SCIT/SLIT)

  • Diagnostic testNAPT

    NAPT test with airborn allergens ( HDM, Threes, Grasses)

06

What researchers measure

Primary outcomes

  1. The effectiveness of AIT treatment assessed by the change in the blood concentration in total en specific IgE .

    The effectiveness of AIT treatment will be analysed by comparing blood results, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up).

    Time frame: before start AIT, every 6 months en after 3 years

  2. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the Lebelscore.

    The effectiveness of AIT treatment will be analysed by comparing the Lebelscores ,assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). Lebelscore has a range between 0 and 12.

    Time frame: Before start AIT, every 6 months en after 3 years

  3. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the SNOT-22.

    The effectiveness of AIT treatment will be analysed by comparing SNOT-22, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). SNOT-22 is sino-nasal outcome test with 22 items which ranges from 0 to 110.

    Time frame: Before start AIT, every 6 months en after 3 years

  4. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the VAS.

    The effectiveness of AIT treatment will be analysed by comparing VAS, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). The visual analogue scale (VAS) ranges from 0 to 10cm for every item.

    Time frame: Before start AIT, every 6 months en after 3 years

  5. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the TNSS.

    The effectiveness of AIT treatment will be analysed by comparing TNSS, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). Total nasal symptom score (TNSS) ranges from 0 to 12.

    Time frame: Before start AIT, every 6 months en after 3 years

  6. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the ACT.

    The effectiveness of AIT treatment will be analysed by comparing ACT, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). ACT is the Asthma control test with scores between 0 and 25. The higher the score the better.

    Time frame: Before start AIT, every 6 months en after 3 years

  7. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the RQLQ.

    The effectiveness of AIT treatment will be analysed by comparing RQLQ, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). RQLQ is the rhinoconjunctivits quality of life questionnaire with scores between 0 and 168. The higher the score of these questionnaires the more discomfort.

    Time frame: Before start AIT, every 6 months en after 3 years

  8. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the TRE.

    The effectiveness of AIT treatment will be analysed by comparing TRE, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). TRE is the therapeutic response evaluation and will be scored between 'much better' and 'much worse'.

    Time frame: Before start AIT, every 6 months en after 3 years

  9. The effectiveness of AIT treatment assessed by the change in the PNIF value.

    The effectiveness of AIT treatment will be analysed by comparing PNIF values assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). PNIF is the peak nasal inspiratory flow with a value between 0 and 370 l/min). The higher the value the less congested the nose is.

    Time frame: Before start AIT, every 6 months en after 3 years

Secondary outcomes

  1. Calculating the cost savings by desensitizing poly-sensitized patients only to the allergen to which they respond most strongly in the NAPT test.

    Time frame: 3 years

  2. Calculating the cost savings by timely stopping AIT treatment in non-responders, which we can define as patients who do not experience subjective or objective improvement after 1 year of treatment.

    Time frame: 3 year

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2020 (actual). Primary completion is estimated for Dec 2026, 77 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2020
First posted
Sep 10, 2020
StartActual
Jul 16, 2020
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04544774
Collaborators
AZ Sint-Jan AV
Responsible party
Laura Van Gerven (prof. dr. Laura Van Gerven, Universitaire Ziekenhuizen KU Leuven) — Principal investigator
First posted
Sep 10, 2020
Start date
Jul 16, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 1, 2026

Study contacts

Margot Vandekerckhove
Contact
margot.vandekerckhove@uzleuven.be
+3216332342
Laura Van Gerven, PhD
Contact
laura.vangerven@uzleuven.be
+3216336340

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion